| 中山醫學大學 |
2021 |
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng, PN; Mo, LR; Chen, CT; Chen, CY; Huang, CF; Kuo, HT; Lo, CC; Tseng, KC; Huang, YH; Tai, CM; Peng, CY; Bair, MJ; Chen, CH; Yeh, ML; Lin, CL; Lin, CY; Lee, PL; Chong, LW; Hung, CH; Chang, T; Huang, JF; Yang, CC; Hu, JT; Lin, CW; Wang, CC; Su, WW; Hsieh, TY; Lin, CL; Tsai, WL; Lee, TH; Chen, GY; Wang, SJ; Chang, CC; Yang, SS; Wu, WC; Huang, CS; Chou, KH; Kao, CN; Tsai, PC; Liu, CH; Lee, MH; Cheng, CY; Tsai, MC; Liu, CJ; Dai, CY; Lin, HC; Kao, JH; Chuang, WL; Yu, ML |
| 臺北醫學大學 |
2014 |
Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways
|
Young, KC;Bai, CH;Su, HC;Tsai, PJ;Pu, CY;Liao, CS;Lin, YM;Lai, HW;Chong, LW;Tsai, YS;Tsao, CW |
